Edition:
United States

BioLine RX Ltd (BLRX.OQ)

BLRX.OQ on NASDAQ Stock Exchange Capital Market

0.85USD
28 Apr 2017
Change (% chg)

$-0.00 (-0.35%)
Prev Close
$0.85
Open
$0.86
Day's High
$0.87
Day's Low
$0.85
Volume
53,213
Avg. Vol
73,328
52-wk High
$1.42
52-wk Low
$0.71

BLRX.OQ

Chart for BLRX.OQ

About

BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in... (more)

Overall

No Ratios Available.

Financials

  BLRX.OQ Industry Sector
P/E (TTM): -- 58.40 30.08
EPS (TTM): -- -- --
ROI: -- -0.42 13.25
ROE: -- 5.87 14.41

BRIEF-BVF Inc reports 18.3 pct passive stake in Bioline RX Ltd

* BVF Inc reports 18.3 percent passive stake in Bioline RX Ltd as on March 31, 2017 Source text:(http://bit.ly/2p0kRot) Further company coverage:

Apr 10 2017

BRIEF-BioLineRx prices $25 mln underwritten public offering

* BioLine rx ltd - priced underwritten public offering of about 29.4 million ADSs at public offering price of $0.85 per ads Source text for Eikon: Further company coverage:

Mar 31 2017

BRIEF-BioLine RX announces underwritten public offering of its american depositary shares

* BioLine RX announces underwritten public offering of its american depositary shares

Mar 30 2017

BRIEF-BiolineRX announces acquisition of Agalimmune Ltd

* Biolinerx announces acquisition of Agalimmune Ltd to accelerate expansion of immuno-oncology pipeline

Mar 23 2017

BRIEF-Biolinerx announces initiation of Immuno-oncology Phase 2 study

* Biolinerx announces initiation of Immuno-oncology Phase 2 study to investigate combination of BL-8040 and keytruda for pancreatic cancer Source text for Eikon: Further company coverage:

Jan 17 2017

BRIEF-Biolinerx reports Q3 financial results

* Bioline RX Ltd - operating loss for three months ended September 30, 2016 amounted to $4.5 million versus operating loss of $3.6 million

Nov 22 2016

BRIEF-BioLine RX in-licenses novel anti-inflammatory treatment for dry eye syndrome under strategic collaboration with major global pharmaceutical company

* BioLine RX Ltd - in addition to des, biolinerx intends to explore potential use of bl-1230 in systemic inflammatory conditions

Nov 21 2016

BRIEF-Bioline RX discloses positive correlative data from phase 2A AML study

* Biolinerx discloses positive correlative data from phase 2a aml study and mechanism-of-action data for bl-8040 oncology platform at ash 2016

Nov 03 2016

More From Around the Web

Earnings vs. Estimates